deltatrials
Completed PHASE2 INTERVENTIONAL 6-arm NCT02308020

A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain

A Phase 2 Study of Abemaciclib in Patients With Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer, Non-small Cell Lung Cancer, or Melanoma

Sponsor: Eli Lilly and Company

Conditions Brain Metastases Breast Cancer Melanoma Non-small Cell Lung Cancer
Interventions Abemaciclib
Updated 21 times since 2017 Last updated: Dec 17, 2020 Started: Apr 20, 2015 Primary completion: Nov 8, 2018 Completion: Nov 8, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Brain Metastases and Breast Cancer and is currently completed. Eli Lilly and Company leads this study, which shows 21 recorded versions since 2015 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~May 2017 · 2 months · monthly snapshot~May 2017 – ~Jun 2017 · 31 days · monthly snapshot~Jun 2017 – ~Sep 2017 · 3 months · monthly snapshot~Sep 2017 – ~Dec 2017 · 3 months · monthly snapshot~Dec 2017 – ~Jan 2018 · 31 days · monthly snapshot~Jan 2018 – ~Mar 2018 · 59 days · monthly snapshot~Mar 2018 – ~Apr 2018 · 31 days · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Oct 2018 · 2 months · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Jan 2020 · 12 months · monthly snapshot~Jan 2020 – ~Jan 2021 · 12 months · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 11 months · monthly snapshot

Change History

21 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jan 2020 — Jan 2021 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 16 earlier versions

  1. Jan 2019 — Jan 2020 [monthly]

    Active Not Recruiting PHASE2

  2. Dec 2018 — Jan 2019 [monthly]

    Active Not Recruiting PHASE2

  3. Nov 2018 — Dec 2018 [monthly]

    Active Not Recruiting PHASE2

  4. Oct 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE2

  5. Aug 2018 — Oct 2018 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  6. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE2

  7. Apr 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

  8. Mar 2018 — Apr 2018 [monthly]

    Recruiting PHASE2

  9. Jan 2018 — Mar 2018 [monthly]

    Recruiting PHASE2

  10. Dec 2017 — Jan 2018 [monthly]

    Recruiting PHASE2

  11. Sep 2017 — Dec 2017 [monthly]

    Recruiting PHASE2

  12. Jun 2017 — Sep 2017 [monthly]

    Recruiting PHASE2

  13. May 2017 — Jun 2017 [monthly]

    Recruiting PHASE2

  14. Mar 2017 — May 2017 [monthly]

    Recruiting PHASE2

  15. Feb 2017 — Mar 2017 [monthly]

    Recruiting PHASE2

  16. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Apr 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eli Lilly and Company
Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Aurora, United States , Barcelona, Spain , Boston, United States , Brussels, Belgium , Chapel Hill, United States , Charleroi, Belgium , Cona, Italy , Duarte, United States , Fort Myers, United States and 32 more locations